Medications for Renal Cell Carcinoma (RCC)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Renal Cell Carcinoma (RCC).
Found 16 Approved Drugs for Renal Cell Carcinoma (RCC)
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Endoglycosidase
OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
Sutent
Generic Name
Sunitinib
Sutent
Generic Name
Sunitinib
Form: Capsule
Method of administration: Oral
FDA approval date: January 26, 2006
Classification: Kinase Inhibitor
Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Form: Injection
Method of administration: Intravenous, Intravascular
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
DOXOrubicin
Brand Names
Doxil, Adriamycin
DOXOrubicin
Brand Names
Doxil, Adriamycin
Form: Injection, Injectable
Method of administration: Intravenous, Intravitreal
FDA approval date: December 23, 1987
Classification: Anthracycline Topoisomerase Inhibitor
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Form: Tablet
Method of administration: Oral
FDA approval date: December 20, 2005
Classification: Kinase Inhibitor
Sorafenib is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma.
Showing 1-5 of 16
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances